XJPX
7917
Market cap543mUSD
Oct 09, Last price
1,208.00JPY
1D
0.75%
1Q
-8.48%
Jan 2017
-58.50%
IPO
88.75%
Name
Fujimori Kogyo Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fujimori Kogyo Co., Ltd., founded in Tokyo, Japan, in 1914, is a global provider of diverse packaging materials, specialized medical and pharmaceutical packaging solutions, and advanced functional components. The company operates through its Life Science, Information Electronics, and Building Materials segments. Its product portfolio features sophisticated optoelectronic offerings, such as MASTACK TFB, a protective film designed for optical applications. The electronics division supplies various products, including MASTACK PC, a heat-resistant protective film; FILMBYNA, a versatile release film used in pharmaceutical patches, adhesive applications, and electronic substrates; CLEAN PACK systems for the secure transfer and transport of semiconductors and precision devices; and META-SEAL FILM, an adhesive film. For the life sciences and general packaging sectors, Fujimori Kogyo manufactures single-use bags essential for bio-pharmaceutical production and microbiological cultures, plant culture bags, and specialized packaging for medical instruments and pharmaceutical products. The company additionally offers PP packaging materials, chemical solution bags, convenient liquid sticks, sealant materials, film separators, and innovative double-structure aerosol systems. Furthermore, its comprehensive range of container solutions includes high-hermetic options, refillable self-standing pouches, collapsible liquid containers, plastic film-lined containers, single-use culture products, liquid-pouch packaging materials suitable for retort sterilization, pouches with a spout, drum liners, and large-capacity liquid transport containers. All these products are marketed under the ZACROS brand name.
Key people
Michihiko Sato
Senior Managing Executive Officer, Director · since 2024
Kimihiko Shiomi
Senior Managing Executive Officer · since 2024
Hiroshi Saga
Managing Executive Officer · since 2023
Kazuma Eguchi
Senior Executive Officer, Chief Director of Information Electronics Business · since 2024
Harutoshi Ishizaka
Senior Executive Officer, Chief Director of Wellness Business, Director of Pharmaceutical and Medical Packaging Business, Director of Business Planning, Manager of Osaka Office · since 2025
Atsushi Takematsu
Senior Executive Officer, Chief Director of Environmental Solution Business · since 2024
Hitoshi Harasawa
Executive Officer, Senior Director of Production, Director of Security Administration · since 2025
Mitsuru Hiramuki
Executive Officer, Director of Human Resources Strategy · since 2024
Takahiro Imura
Executive Officer, Director of Advanced Materials Business in Main Information & Electronics Business Unit · since 2024
Shinichiro Kimura
Executive Officer, Director of Functional Containers in Main Environmental Solution Business Unit, Director of Business Planning · since 2024
Daisuke Kobayakawa
Executive Officer, Director of Smart Electronics Business · since 2025
Executive Officer · since 2025
Tomoyuki Sasaki
Executive Officer, Director of Byphas Business Promotion, Director of Advanced Medical Business Promotion · since 2025
Toyoaki Suzuki
Executive Officer, Director of Research Institute · since 2019
Akihiko Fujimori
Chairman of the Board · since 2024
Nobuhiko Fujimori
Director · since 2024
Eishi Fuyama
Director · since 2025
Norihiro Kusaka
President of Subsidiary, Director · since 2023
Taku Shimoda
President, Representative Director · since 2024
Kumi Izawa
Independent Director · since 2024
Headquarters & legal address
小石川1-1-1
東京都 文京区 112-0002
JP
東京都 文京区 112-0002
JP
Address
1-1-1 Koishikawa
Bunkyo-ku Tokyo 112-0002
JP
Bunkyo-ku Tokyo 112-0002
JP
Previous name
藤森工業株式会社
Other language
ZACROS Corporation
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||